5-Aminosalicylic acid for treatment of irritable bowel syndrome: A protocol for a systematic review and meta-analysis
- PMID: 32118774
- PMCID: PMC7478678
- DOI: 10.1097/MD.0000000000019351
5-Aminosalicylic acid for treatment of irritable bowel syndrome: A protocol for a systematic review and meta-analysis
Abstract
Background: The global prevalence of irritable bowel syndrome (IBS) is estimated to be as high as 15%, and it is estimated that IBS has a prevalence of approximately 10% to 20% in Western countries. Some trials showed mesalazine (5-aminosalicylic acid [5-ASA]) might be effective for IBS, but the results still need to be confirmed. Hence, this meta-analysis is designed to assess the efficacy and safety of mesalazine for IBS in adults and children.
Methods: We conducted a comprehensive database search for randomized trials of mesalazine for IBS in PubMed, EMBASE, and the Cochrane Library. The search strategy was performed from inception to December 31, 2019, without restrictions on publication status and language. The reference lists of the included articles were also checked to identify additional studies for potential inclusion. Two reviewers will independently review all literature for inclusion and assess their risk of bias. Two reviewers will independently extract data from eligible studies based on a pre-designed standardized form. Any disagreements will be resolved by consensus. Stata SE 15.0 software will be used for data synthesis.
Results: This is the first meta-analysis focusing on mesalazine for the treatment of IBS. We predict it will provide high-quality synthesis on existing evidence for IBS and a relatively comprehensive reference for clinical practice and development of clinical guidelines for IBS.
Conclusion: This protocol outlined the significance and methodological details of a systematic review of mesalazine for IBS. This ongoing meta-analysis will provide high-quality synthesis on existing evidence for IBS.
Registration: The meta-analysis has been prospectively registered in PROSPERO (CRD42019147860).
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures
Similar articles
-
Effectiveness of mesalazine to treat irritable bowel syndrome: A meta-analysis.Medicine (Baltimore). 2019 Jul;98(28):e16297. doi: 10.1097/MD.0000000000016297. Medicine (Baltimore). 2019. PMID: 31305414 Free PMC article.
-
Randomised clinical trial and meta-analysis: mesalazine treatment in irritable bowel syndrome-effects on gastrointestinal symptoms and rectal biomarkers of immune activity.Aliment Pharmacol Ther. 2022 Sep;56(6):968-979. doi: 10.1111/apt.17182. Epub 2022 Aug 8. Aliment Pharmacol Ther. 2022. PMID: 35942522 Free PMC article.
-
Electroacupuncture for patients with irritable bowel syndrome: A systematic review and meta-analysis protocol.Medicine (Baltimore). 2018 Aug;97(31):e11627. doi: 10.1097/MD.0000000000011627. Medicine (Baltimore). 2018. PMID: 30075541 Free PMC article.
-
Efficacy of opioid receptor modulators in patients with irritable bowel syndrome: A systematic review and meta-analysis.Medicine (Baltimore). 2021 Jan 29;100(4):e24361. doi: 10.1097/MD.0000000000024361. Medicine (Baltimore). 2021. PMID: 33530231 Free PMC article.
-
Vitamin D Supplementation and Mental Health in Inflammatory Bowel Diseases and Irritable Bowel Syndrome Patients: A Systematic Review.Nutrients. 2021 Oct 19;13(10):3662. doi: 10.3390/nu13103662. Nutrients. 2021. PMID: 34684663 Free PMC article.
Cited by
-
Efficacy of Jawarish Shahi a herbal formulation in irritable bowel syndrome: An open-labeled single-arm clinical trial.J Tradit Complement Med. 2022 Apr 22;12(6):529-535. doi: 10.1016/j.jtcme.2022.04.004. eCollection 2022 Nov. J Tradit Complement Med. 2022. PMID: 36325243 Free PMC article.
-
Mast Cell Regulation and Irritable Bowel Syndrome: Effects of Food Components with Potential Nutraceutical Use.Molecules. 2020 Sep 20;25(18):4314. doi: 10.3390/molecules25184314. Molecules. 2020. PMID: 32962285 Free PMC article. Review.
-
Cotton swabs decorated with Ag@BPQD for the fluorescence determination of 3-aminosalicylic and 5-aminosalicylic acid.Mikrochim Acta. 2023 Feb 7;190(3):82. doi: 10.1007/s00604-023-05665-7. Mikrochim Acta. 2023. PMID: 36746802
-
A review of the biological and pharmacological activities of mesalazine or 5-aminosalicylic acid (5-ASA): an anti-ulcer and anti-oxidant drug.Inflammopharmacology. 2021 Oct;29(5):1279-1290. doi: 10.1007/s10787-021-00856-1. Epub 2021 Aug 19. Inflammopharmacology. 2021. PMID: 34410540
References
-
- Lacy BE. Emerging treatments in neurogastroenterology: eluxadoline – a new therapeutic option for diarrhea-predominant IBS. Neurogastroenterol Motil 2016;28:26–35. - PubMed
-
- Ford AC, Talley NJ. Irritable bowel syndrome. BMJ 2012;345:1–8. e5836. - PubMed
-
- Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. Gastroenterology 2016;150:1257–61. - PubMed
-
- Oswiecimska J, Szymlak A, Roczniak W, et al. New insights into the pathogenesis and treatment of irritable bowel syndrome. Adv Med Sci 2017;62:17–30. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources